Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
75
VERA Quote, Financials, Valuation and Earnings
Last price:
$55.80
Seasonality move
:
12.48%
Day range:
$53.26 - $55.00
52-week range:
$18.53 - $55.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.64x
Volume:
845K
Avg. volume:
1.8M
1-year change:
27.42%
Market cap:
$3.4B
Revenue:
--
EPS (TTM):
-$3.99
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
-- | -$1.13 | -- | -76.12% | $75.15 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 98.51% | -58.59% | $491.92 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 66.86% | -2.57% | $214.78 |
|
KRYS
Krystal Biotech, Inc.
|
$93.4M | $1.12 | 16.27% | 5.57% | $229.00 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$247.7M | -$1.99 | 200.72% | -82.86% | $603.47 |
|
MNKD
MannKind Corp.
|
$80.2M | $0.03 | 30.4% | 17.65% | $9.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
$53.91 | $75.15 | $3.4B | -- | $0.00 | 0% | -- |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$398.51 | $491.92 | $52.6B | 1,657.01x | $0.00 | 0% | 16.35x |
|
INSM
Insmed, Inc.
|
$176.77 | $214.78 | $37.7B | -- | $0.00 | 0% | 75.23x |
|
KRYS
Krystal Biotech, Inc.
|
$253.36 | $229.00 | $7.3B | 38.00x | $0.00 | 0% | 20.26x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$602.21 | $603.47 | $13.7B | -- | $0.00 | 0% | 18.03x |
|
MNKD
MannKind Corp.
|
$5.93 | $9.61 | $1.8B | 62.95x | $0.00 | 0% | 5.83x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
16.22% | 2.262 | 4.16% | 11.88x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | 0.141 | 0.19% | 9.43x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
35.63% | -0.048 | 3.33% | 3.14x |
|
MNKD
MannKind Corp.
|
124.56% | 0.023 | 13.7% | 2.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VERA
Vera Therapeutics, Inc.
|
-$564K | -$83.9M | -48.69% | -55.53% | -- | -$62M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$268.8M | -$114M | -32.91% | -40.56% | -39.68% | $76M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
Vera Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VERA or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of 20.1%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About VERA or ALNY?
Vera Therapeutics, Inc. has a consensus price target of $75.15, signalling upside risk potential of 39.41%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 20.65%. Given that Vera Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is VERA or ALNY More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock VERA or ALNY?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or ALNY?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Vera Therapeutics, Inc.'s net income of -$80.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,657.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 16.35x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M ALNYAlnylam Pharmaceuticals, Inc.16.35x 1,657.01x $1.2B $251.1M
-
Which has Higher Returns VERA or INSM?
Insmed, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of -259.95%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About VERA or INSM?
Vera Therapeutics, Inc. has a consensus price target of $75.15, signalling upside risk potential of 39.41%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 21.6%. Given that Vera Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 INSMInsmed, Inc.17 1 0 -
Is VERA or INSM More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock VERA or INSM?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or INSM?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Vera Therapeutics, Inc.'s net income of -$80.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 75.23x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M INSMInsmed, Inc.75.23x -- $142.3M -$370M
-
Which has Higher Returns VERA or KRYS?
Krystal Biotech, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of 81.15%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About VERA or KRYS?
Vera Therapeutics, Inc. has a consensus price target of $75.15, signalling upside risk potential of 39.41%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $229.00 which suggests that it could fall by -9.62%. Given that Vera Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 KRYSKrystal Biotech, Inc.10 1 0 -
Is VERA or KRYS More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.
-
Which is a Better Dividend Stock VERA or KRYS?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or KRYS?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Vera Therapeutics, Inc.'s net income of -$80.3M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 38.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 20.26x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M KRYSKrystal Biotech, Inc.20.26x 38.00x $97.8M $79.4M
-
Which has Higher Returns VERA or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of -39.75%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M MDGLMadrigal Pharmaceuticals, Inc.93.57% -$5.08 $972.1M -
What do Analysts Say About VERA or MDGL?
Vera Therapeutics, Inc. has a consensus price target of $75.15, signalling upside risk potential of 39.41%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 0.21%. Given that Vera Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Vera Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 MDGLMadrigal Pharmaceuticals, Inc.13 1 0 -
Is VERA or MDGL More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.
-
Which is a Better Dividend Stock VERA or MDGL?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or MDGL?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Vera Therapeutics, Inc.'s net income of -$80.3M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 18.03x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M MDGLMadrigal Pharmaceuticals, Inc.18.03x -- $287.3M -$114.2M
-
Which has Higher Returns VERA or MNKD?
MannKind Corp. has a net margin of -- compared to Vera Therapeutics, Inc.'s net margin of 9.72%. Vera Therapeutics, Inc.'s return on equity of -55.53% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VERAVera Therapeutics, Inc.-- -$1.26 $476.1M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About VERA or MNKD?
Vera Therapeutics, Inc. has a consensus price target of $75.15, signalling upside risk potential of 39.41%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 62.08%. Given that MannKind Corp. has higher upside potential than Vera Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Vera Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VERAVera Therapeutics, Inc.10 2 0 MNKDMannKind Corp.8 0 0 -
Is VERA or MNKD More Risky?
Vera Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.928%.
-
Which is a Better Dividend Stock VERA or MNKD?
Vera Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VERA or MNKD?
Vera Therapeutics, Inc. quarterly revenues are --, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Vera Therapeutics, Inc.'s net income of -$80.3M is lower than MannKind Corp.'s net income of $8M. Notably, Vera Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 62.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics, Inc. is -- versus 5.83x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VERAVera Therapeutics, Inc.-- -- -- -$80.3M MNKDMannKind Corp.5.83x 62.95x $82.1M $8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
